Mixed-phenotype acute leukemia (MPAL) encompasses a heterogeneous group of rare leukemias in which assigning a single lineage of origin is not possible. Over the years there has been much controversy regarding how to diagnose and treat patients with MPAL.
In this talk we will review the most current WHO criteria for diagnosing MPAL. We will also discuss current approaches and consideration in choosing therapy in this rare group of patients. Finally, recent high impact publications reported on the genetic landscape of MPAL. We will discuss these findings and their impact on potential targeted therapies for these leukemias.